Navigation Links
Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
Date:5/19/2008

Alzheimer's disease in the in the developed countries with the number increasing also in developing countries as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The company has a broad proprietary immunotherapy platform for both passive and active immunization against Alzheimer's disease. Also, Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
2. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
3. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
4. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
5. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
8. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Four-dimensional (4-D) printing develops ... on external stimuli such as changes in temperature. ... disruptive effect in multiple industries.  In the near ... by printing objects ranging from human organs to ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... LSU associate professor of chemistry in the College of ... honor for scientists and engineers in the early stages ... Award for Scientists and Engineers, or PECASE. "I ... award. LSU is a rich environment for accomplishing nanoscience ...
... ... ... ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Atrium Innovations Announces Third Quarter Financial Results of 2010 2Atrium Innovations Announces Third Quarter Financial Results of 2010 3Atrium Innovations Announces Third Quarter Financial Results of 2010 4Atrium Innovations Announces Third Quarter Financial Results of 2010 5Atrium Innovations Announces Third Quarter Financial Results of 2010 6Atrium Innovations Announces Third Quarter Financial Results of 2010 7Atrium Innovations Announces Third Quarter Financial Results of 2010 8Atrium Innovations Announces Third Quarter Financial Results of 2010 9Atrium Innovations Announces Third Quarter Financial Results of 2010 10Atrium Innovations Announces Third Quarter Financial Results of 2010 11Atrium Innovations Announces Third Quarter Financial Results of 2010 12Atrium Innovations Announces Third Quarter Financial Results of 2010 13Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 2Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 3Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 4Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 5Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 6Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 7Neuro-Biotech Corp. Neuroceuticals® : A solution to feed the brain 8
(Date:8/21/2014)... SHELTON, Conn. , Aug. 21, 2014 ... on the growing mobile commerce market, announced today that ... purchase common stock to be issued in its proposed ... been approved for listing on The Nasdaq Capital Market, ... of the common stock and warrants, and will trade ...
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... that resists infection, yet 10% of the world's agricultural ... fungi, and viruses. Understanding how disease resistance works may ... study published online this week in the open-access journal ... how one aspect of the plant immune system is ...
... and separate a wide class of swimming bacteria ... at Argonne National Laboratory, Illinois Institute of technology, ... UK. This device could have enormous applications in ... medical diagnostic kits and bioanalysis. , The technique ...
... person, it triggers a series of biochemical reactions in immune-system ... , Usually, the result is an effective immune response, leading ... recovery. But in the case of some of the world’s ... as well as the influenza virus strain responsible for the ...
Cached Biology News:Researchers develop technique for bacteria crowd control 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 3
... Coating Stabilizer has been developed specifically ... immobilized proteins on microwell plates/strips. ... activity of the antibody or protein ... components. Product is filtered at ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: